Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, Brexpiprazole (Rexulti®) cannot be endorsed for use within NHS Wales for the treatment of schizophrenia in adult patients. |
||
|
||
Medicine details |
||
| Medicine name | brexpiprazole (Rexulti®) | |
| Formulation | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg film-coated tablet | |
| Reference number | 1372 | |
| Indication | Treatment of schizophrenia in adult patients. |
|
| Company | Otsuka Pharmaceutical (UK) Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 19/12/2018 | |